Clearside Biomedical to Participate in Upcoming Investor Events in November and December 2021
Clearside Biomedical, a biopharmaceutical firm focused on ocular therapies, announced its participation in four upcoming virtual investor events, showcasing its innovative suprachoroidal space (SCS) delivery system. Key events include the Stifel 2021 Virtual Healthcare Conference on November 17, Piper Sandler Annual Conference from November 29 to December 2, BTIG Ophthalmology Day on November 30, and UBS Ophthalmology Day on December 6. The first product, XIPERE, received FDA approval in October 2021, enhancing treatment options for eye diseases.
- None.
- None.
ALPHARETTA, Ga., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it will participate in the following investor events, which will each be held in a virtual meeting format:
Stifel 2021 Virtual Healthcare Conference
Wednesday, November 17, 2021 at 8:00 am ET
Piper Sandler 33rd Annual Virtual Healthcare Conference
Monday, November 29 – Thursday, December 2, 2021
Recorded Presentation will be available: Monday, November 22, 2021, at 10:00 a.m. ET
BTIG Ophthalmology Day
Tuesday, November 30, 2021
UBS Ophthalmology Day
Monday, December 6, 2021
A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021. For more information, please visit www.clearsidebio.com.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
What investor events is Clearside Biomedical participating in November and December 2021?
What is the significance of the SCS delivery system developed by Clearside Biomedical?
When was Clearside Biomedical's first product, XIPERE, approved by the FDA?
How can investors access the webcasts of Clearside Biomedical's presentations?
